S. Curescu

Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec et al. · Journal of Clinical Oncology · 2011 · 279 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC

W. Brugger, Nadja Triller, Maria Błasińska-Morawiec et al. · Journal of Clinical Oncology · 2009 · 57 citations

Medicine, Oncology, Pharmacology +17

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17